Status:
TERMINATED
Cardiopulmonary Bypass-Induced Lymphocytopenia and the Potential Effects of Protease Inhibitor
Lead Sponsor:
Mayo Clinic
Conditions:
Cardiopulmonary Bypass
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
In previous studies, 90% of patients who underwent elective cardiopulmonary bypass procedure manifested CD4 counts of less than 500 cells/microliter in the immediate (day 1) post-operative period. Thi...
Detailed Description
See Brief Summary.
Eligibility Criteria
Inclusion
- Any patient undergoing elective (non-emergency) cardiopulmonary bypass for coronary artery bypass grafting, cardiac valve replacement, or both.
Exclusion
- A dozen different medical conditions and two dozen medical contraindications.
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT00385450
Start Date
October 1 2006
End Date
October 1 2008
Last Update
April 28 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905